AstraZeneca Expects Phase III Zactima Data For NSCLC In 2008
This article was originally published in The Pink Sheet Daily
Executive Summary
Company completes enrollment in ZEST trial evaluating the oral anti-cancer drug vandetanib compared to Tarceva.
You may also be interested in...
Two More Phase III Zactima Trials Reach Full Enrollment
AstraZeneca’s investigational drug for non-small cell lung cancer remains on track for an NDA filing this year.
Two More Phase III Zactima Trials Reach Full Enrollment
AstraZeneca’s investigational drug for non-small cell lung cancer remains on track for an NDA filing this year.
AstraZeneca Executive VP, Discovery Research, Jan Lundberg: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
AstraZeneca's chief of discovery research discusses his company's pipeline, its plans related to the acquisitions of MedImmune and CAT, and whether the Exanta compound has any developmental future with "The Pink Sheet" DAILY.